Investor Relations

 

Common Stock

Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Overview

We aspire to become a world leader in AI-immunology, decoding the human immune system to develop effective immunotherapies for cancer and infectious diseases based on deep biological insights. We believe our ground-breaking AI-Immunology™ models PIONEER™, EDEN™ and RAVEN™, trained to simulate the immune system, can be harnessed to rapidly and cost-effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. We have two personalized cancer immunotherapies in the clinic and are advancing a portfolio of vaccines to treat bacterial and viral infections. With an experienced management team, strong IP portfolio and scalable business model, Evaxion is well positioned for rapid growth.

Are you eager to deep-dive into Evaxion's business?
Download our company presentation below, or click here to see all our latest presentations.

Latest News

Press Release

May 23, 2024

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

EVX-01 induced positive clinically relevant immune responses in all assessed patients Booster immunizations tended to increase the immune response The observed immune responses were mediated by both CD4+ and CD8+ T-cells COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S

Press Release

May 10, 2024

Evaxion Receives Nasdaq Notification

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the “Letter”) from the

Press Release

April 17, 2024

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX)

Press Release

Apr 2, 2024

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus  in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promising

Event

May 31, 2024

Event

Jul 12, 2024

Event

Aug 7, 2024

LATEST QUARTERLY EARNINGS (NASDAQ)

Subscribe to Investor Email Alerts

Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts.